MedTrace Logo

Involvement of the Septal Nuclei of the Human Brain in Alcohol Use Disorder

NCT06866379 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-06-11

No results posted yet for this study

Summary

Alcohol activates reward systems in different brain areas, i.e., the nucleus accumbens, dorsal striatum, extended amygdala, and prefrontal cortex. These areas are all part of the reward neurocircuitry, which plays an important role in the development of addiction.

A former study performed on rodents has shown that a specific area of the forebrain, the septal nuclei, is associated with the feeling of reward and, hence, addiction when stimulated. However, whether the septal area is involved in reward and addiction in humans is sparsely investigated.

The purpose of this brain-imaging study is to assess how the septal nuclei react to alcohol-related pictures shown to participants diagnosed with alcohol use disorder while lying in an MRI scanner, compared to people without a diagnosis of alcohol use disorder. This might give us a better understanding of how the septal nuclei is involved in reward and addiction.

Conditions

Interventions

OTHER

Brain imaging

fMRI session with the ALCUE paradigme.

Sponsors & Collaborators

  • Neurobiology Research Unit, Rigshospitalet

    collaborator UNKNOWN

  • The foundation of Mr. Ivan Nielsen

    collaborator UNKNOWN

  • King Christian X foundation

    collaborator UNKNOWN

  • Anders Fink-Jensen, MD, DMSci

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-07
Primary Completion
2025-09-01
Completion
2025-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06866379 on ClinicalTrials.gov